HSBC's Ori Hershkovitz reiterated a Buy with a $23 target, implying 31% upside. Teva's Alpha Score stands at 63. The stock dropped 12% over the past year.
Teva Pharmaceutical Industries fell 2.8% last week on Wall Street, with losses in four of the five sessions. The stock now sits roughly 12% below its year-ago level, erasing some of the 60% rally it posted in 2024.
HSBC analyst Ori Hershkovitz sees a different trajectory. He reiterated a Buy rating with a $23 price target, implying roughly 31% upside from Friday's close near $17.50. The firm's outlook rests on Teva's pipeline progress and generic-market positioning, Hershkovitz said in a note.
Teva carries an Alpha Score of 63 out of 100, labeled Moderate, within the Healthcare sector. The rating reflects balanced fundamentals without a strong directional tilt.
The stock has pulled back steadily since early February, when it traded above $19. The weekly slide accelerated after the company's fourth-quarter report, which missed revenue estimates on softer-than-expected U.S. generics sales. Teva management reaffirmed full-year guidance at the time, pointing to new product launches and cost savings as recovery levers.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.